Understanding the fate (pharmacokinetics or PK) and action (pharmacodynamics or PD) of a drug is essential for preclinical and clinical drug development as well as the practice of precision medicine. The MPCBSR helps investigators study new therapeutics for the leading causes of cancer deaths within the cancer center’s catchment area by providing comprehensive services for
The technologies and state-of-the-art instruments available at the MPCBSR support a wide variety of molecular pharmacology and chemical biology studies. Our faculty and staff members are worldwide leaders in the fields and have the expertise to offer guidance and training for scientists on the principles and technologies used in anticancer pharmacology and chemical biology.
The MPCBSR provides essential and a broad spectrum of services for the assessment of new therapeutics, including high-quality collection and management of clinical trial specimens and determination of clinical PK/PD and potential drug-drug interactions (DDI), pharmacological studies on novel therapeutics in preclinical models, including DM/PK/PD, on-target mechanisms, biomarkers, and combination effects, and chemical synthesis of new compounds and drug delivery nanomaterials for improved therapy.
We offer timely, 24/7 collection, processing, and management of specimens for clinical PK/PD and safety studies. The MPCBSR conducts around 3,000 patient specimen collections each year. Many involve unique protocols and processing requirements. We oversee virtually all patient specimen collection for oncology clinical trials at the cancer center.
We also help investigators develop and use new assays to:
The MPCBSR assists UCDCCC investigators in evaluating new therapeutics that are translatable to the clinic, by using clinically relevant animal models, cell lines and organoids. We have many established assays and the capability to develop new methods to:
We also provide one-of-a-kind bioengineered RNA molecules (including miRNAs, siRNAs, aptamers and other forms of small RNAs) to study cancer biology and investigate new therapeutics, which are made in vivo and distinguished from conventional agents synthesized in vitro.
The MPCBSR provides a wide variety of chemical compounds to investigators and offers chemistry support for their cancer research. Examples of services include:
Investigators working with the MPCBSR gain access to state-of-the-art equipment and instrumentation, including:
For more details about the rate, please contact: 916-734-0905
Members of the cancer center receive priority access and subsidized rates for Shared Resources services. Not yet a member? Learn about the benefits and privileges of cancer center membership.
We’re here to support your cancer research study. Fill out a request to use our services.
NOTE: A PPMS account is required. View our quick start guide for creating an account or set up an account.
For questions about molecular pharmacology and chemical biology or how our faculty can assist you, call the lab at 916-734-1566 or contact us.
Technical Director
(Clinical Specimens Collection, Processing and Management)
Email: axmartinez@ucdavis.edu
Technical Director
(Chemical Biology Studies)
Phone: 916-734-0905
Email: ruiwu.liu@ucdmc.ucdavis.edu
Manager
(Pharmacological Studies; DM/PK/PD)
Email: mjttu@ucdavis.edu
Read about FDA regulations pertaining to drug development:
UC Davis Comprehensive Cancer Center members can access the Lawrence Livermore National Laboratory (LLNL) National User Resource for Biological Accelerator Mass Spectrometry (bioAMS). The bioAMS facility supports investigators studying the behavior of new drug candidates. For more information about cancer research services at LLNL, contact Matt Coleman.
CCSG and MPCBSR Acknowledgement: the authors wish to acknowledge the support of the UC Davis Comprehensive Cancer Center Molecular Pharmacology and Chemical Biology Shared Resource, supported by the National Cancer Institute of the National Institutes of Health under award number P30CA093373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This resource is funded by the Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373). Publications that have utilized facility resources, services or scientific data generated by the resource should acknowledge the resource or the assistance provided by resource staff and cite the NCI CCSG. An electronic copy of the publication should also be sent to the resource directors.